$11.58 0.00 (%) Omeros Corp - NASDAQ

Oct. 29, 2014 | 04:00 PM

Partner Headlines

  1. Morning Market Losers

    Benzinga | Oct. 21, 2014 | 10:07AM EST
  2. Benzinga's Top #PreMarket Losers

    Benzinga | Oct. 21, 2014 | 08:21AM EST
  3. US Stock Futures Edge Higher Ahead Of Jobless Claims Data

    Benzinga | Apr. 3, 2014 | 07:34AM EST
  4. Omeros Announces Proposed Public Offering of Common Stock

    Benzinga | Mar. 13, 2014 | 16:37PM EST
  5. Benzinga's Top #PreMarket Gainers

    Benzinga | Feb. 5, 2014 | 08:06AM EST
  6. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 18, 2013 | 08:36AM EST
  7. UPDATE: FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies

    Benzinga | Dec. 18, 2013 | 07:06AM EST
  8. Hearing Wedbush Names Omeros Top Pick for 2014; $32 PT

    Benzinga | Dec. 16, 2013 | 09:45AM EST
  9. Omeros Announces FDA Accepts Omidria as Brand Name for OMS302

    Benzinga | Nov. 20, 2013 | 07:01AM EST
  10. Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration

    Benzinga | Nov. 5, 2013 | 07:13AM EST
  11. Omeros Reports Positive OMS721 Data

    Benzinga | Nov. 5, 2013 | 07:06AM EST
  12. Omeros Says FDA Has Agreed to Pediatric Study Plan for OMS302

    Benzinga | Oct. 15, 2013 | 07:01AM EST
  13. Benzinga's Top Pre-Market Gainers

    Benzinga | Oct. 3, 2013 | 08:12AM EST
  14. Shares Of Omeros Rocket Higher As Wedbush Lifts Target, Sees Near Tripling In Stock Price

    Benzinga | Oct. 2, 2013 | 12:09PM EST
  15. FDA, EMA Accept OMS302 Marketing Applications for Review

    Benzinga | Oct. 2, 2013 | 07:03AM EST
  16. Omeros Announces FDA Orphan Drug Designation for OMS824 for Huntington's Disease

    Benzinga | Sep. 30, 2013 | 07:05AM EST
  17. Omeros Initiates Phase 2 Clinical Trial with OMS824

    Benzinga | Sep. 19, 2013 | 07:01AM EST
  18. Benzinga's Top Pre-Market Losers

    Benzinga | Sep. 17, 2013 | 08:17AM EST
  19. Wedbush Reiterates Outperform Rating on Omeros on Potential Increased OMS302 Use

    Benzinga | Sep. 16, 2013 | 12:18PM EST
  20. Morning Market Movers

    Benzinga | Sep. 16, 2013 | 10:21AM EST
  21. Omeros Reports Additional Positive Results from Phase 1 OMS824 Clinical Trial

    Benzinga | Sep. 12, 2013 | 07:02AM EST
  22. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer

    Benzinga | Aug. 13, 2013 | 07:08AM EST
  23. Shares of Omeros Bounce Over $5.40 Following Mid-Day Comments from MLV's Zavoico

    Benzinga | Aug. 12, 2013 | 14:43PM EST
  24. Omeros Submits NDA for OMS302, Wedbush Says Approval Could be 'Catalyst' for Stock

    Benzinga | Aug. 1, 2013 | 12:09PM EST
  25. UPDATE: Canaccord Genuity Cuts PT to $13 on Omeros Corporation on Phase 3 Endpoint Miss

    Benzinga | Dec. 28, 2012 | 02:12AM EST
  26. Stocks To Watch For December 28, 2012

    Benzinga | Dec. 27, 2012 | 18:42PM EST
  27. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program

    Benzinga | Dec. 6, 2012 | 00:33AM EST
  28. Omeros Announces Promising Data from Phase 1 OMS824 Clinical Trial

    Benzinga | Dec. 6, 2012 | 00:13AM EST
  29. Omeros Responds to Misleading Announcement Concerning Settlement with Former CFO Richard J. Klein

    Benzinga | Nov. 9, 2012 | 00:04AM EST
  30. Omeros' Ophthalmology Announces Clinical Trial Data

    Benzinga | Nov. 5, 2012 | 00:17AM EST
  31. From Earlier: Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program

    Benzinga | Oct. 2, 2012 | 03:19AM EST
  32. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program

    Benzinga | Sep. 6, 2012 | 01:04AM EST
  33. Mead Johnson Nutrition, DaVita Among Stocks Hitting 52-Week Highs Friday

    FoxBusiness | Jun. 22, 2012 | 10:35AM EST
  34. Benzinga's Microcap Movers for Tuesday January 10, 2012

    Benzinga | Jan. 10, 2012 | 15:00PM EST
Trading Center